Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: Involvement of hypothalamic–pituitary–adrenal axis, cAMP signaling aspects and antioxidant defense system

Olfactory bulbectomy (OBX) model has been proposed as a well documented model of depression. Accumulated evidences suggest that cAMP selective PDE4 enzyme plays an important role in the pathophysiology of depression disorder. Moreover, PDE4 inhibitors have shown antidepressant-like effect in behavio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacology, biochemistry and behavior biochemistry and behavior, 2015-05, Vol.132, p.20-32
Hauptverfasser: Jindal, Ankur, Mahesh, Radhakrishnan, Bhatt, Shvetank
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 32
container_issue
container_start_page 20
container_title Pharmacology, biochemistry and behavior
container_volume 132
creator Jindal, Ankur
Mahesh, Radhakrishnan
Bhatt, Shvetank
description Olfactory bulbectomy (OBX) model has been proposed as a well documented model of depression. Accumulated evidences suggest that cAMP selective PDE4 enzyme plays an important role in the pathophysiology of depression disorder. Moreover, PDE4 inhibitors have shown antidepressant-like effect in behavioral despair models. However, the potential of PDE4 inhibitors to produce antidepressant-like effect in OBX model and their underlying mechanism(s) has not been adequately addressed. The present study was designed to investigate the possible antidepressant-like effects and underlying mechanism of rolipram in OBX model. The effects of rolipram were measured in a battery of behavioral paradigms, including hyperactivity in open field test (OFT), anhedonia behavior in sucrose consumption test, open arm activity in elevated plus maze test (EPM) and emotional scores in hyperemotionality test. The underlying signaling mechanisms were also investigated by measuring serum corticosterone (CORT), brain-derived neurotrophic factor (BDNF) and brain oxidant/antioxidant levels. Treatment with rolipram (0.5 and 1mg/kg, p.o., 14days) significantly improved the behavioral anomalies (decreased the hyperactivity, open arm activity and hyperemotionality scores, whereas, increased sucrose consumption). Further, rolipram significantly decreased the CORT level and increased cAMP, pCREB and BDNF levels. Additionally, rolipram reduced oxidative–nitrosative stress markers (lipid peroxidation and nitrite levels) and restored the antioxidant enzyme level, including reduced glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT), indicating attenuation of oxidative–nitrosative stress. Our results revealed that antidepressant-like effects of rolipram in OBX model may be mediated by modulating the hypothalamic–pituitary–adrenal (HPA) axis activity, increasing the cAMP signaling aspects and restoring the antioxidant mechanisms. •OBX rats showed depression-like behavior.•OBX rats showed alter HPA axis, oxidant/antioxidant system and cAMP signaling.•Rolipram reversed the depression-like behavior in OBX rats.•Rolipram normalized alter HPA axis, oxidant/antioxidant system and cAMP signaling.•Rolipram effect may relate to HPA axis, cAMP/CREB/BDNF and antioxidant mechanism.
doi_str_mv 10.1016/j.pbb.2015.02.017
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826611335</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091305715000581</els_id><sourcerecordid>1732832133</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-f5ee916482ec3f7b7c63a22333145621c16b0d5c7efe6848ade33e06d9b9f7e13</originalsourceid><addsrcrecordid>eNqFks1u1DAQxyMEokvhAbggHzl0F38kcRZOVQWlUhEcytly7El3Vokd7Oyq4cQ78Ia98hLMagtHOIzGsn_zH89HUbwUfCW4qN9sV2PbriQX1YrLFRf6UbEQjVbLSmj9uFhwvhZLxSt9UjzLecs5L2WtnxYnstJCCl0uil838wisZOMmZjKPkCdINgOD8H0egGHYYItTTGcsxR7HZAeWILsdZNbCxu4xJtszDx06nDLxLPaddRQxs3bXt0DHYWZD9NBnFjtCRxLIGMNbdhX2sd_DAGE6PG3mMU4b29sB3f2PnyNOO5xsmulsfYJAiewd5jPmzj99YRlv6QbDLbN5pDSZ2eDJJox36MkffgWBaskzVTU8L550ts_w4sGfFl8_vL-5-Li8_nx5dXF-vXRlJadlVwGsRV02EpzqdKtdrayUSilRVrUUTtQt95XTJF43ZWM9KAW89ut23WkQ6rR4fdQdU_xGfZrMgNlB39sAcZeNaGRdC6FU9X9UK9koSSyh4oi6FHNO0Jkx4UDNMYKbwzqYraF1MId1MFwaWgeKefUgv2sH8H8j_syfgHdHgGYDe4RkskMIDjwm6qjxEf8h_xvuqs73</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1732832133</pqid></control><display><type>article</type><title>Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: Involvement of hypothalamic–pituitary–adrenal axis, cAMP signaling aspects and antioxidant defense system</title><source>Elsevier ScienceDirect Journals</source><creator>Jindal, Ankur ; Mahesh, Radhakrishnan ; Bhatt, Shvetank</creator><creatorcontrib>Jindal, Ankur ; Mahesh, Radhakrishnan ; Bhatt, Shvetank</creatorcontrib><description>Olfactory bulbectomy (OBX) model has been proposed as a well documented model of depression. Accumulated evidences suggest that cAMP selective PDE4 enzyme plays an important role in the pathophysiology of depression disorder. Moreover, PDE4 inhibitors have shown antidepressant-like effect in behavioral despair models. However, the potential of PDE4 inhibitors to produce antidepressant-like effect in OBX model and their underlying mechanism(s) has not been adequately addressed. The present study was designed to investigate the possible antidepressant-like effects and underlying mechanism of rolipram in OBX model. The effects of rolipram were measured in a battery of behavioral paradigms, including hyperactivity in open field test (OFT), anhedonia behavior in sucrose consumption test, open arm activity in elevated plus maze test (EPM) and emotional scores in hyperemotionality test. The underlying signaling mechanisms were also investigated by measuring serum corticosterone (CORT), brain-derived neurotrophic factor (BDNF) and brain oxidant/antioxidant levels. Treatment with rolipram (0.5 and 1mg/kg, p.o., 14days) significantly improved the behavioral anomalies (decreased the hyperactivity, open arm activity and hyperemotionality scores, whereas, increased sucrose consumption). Further, rolipram significantly decreased the CORT level and increased cAMP, pCREB and BDNF levels. Additionally, rolipram reduced oxidative–nitrosative stress markers (lipid peroxidation and nitrite levels) and restored the antioxidant enzyme level, including reduced glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT), indicating attenuation of oxidative–nitrosative stress. Our results revealed that antidepressant-like effects of rolipram in OBX model may be mediated by modulating the hypothalamic–pituitary–adrenal (HPA) axis activity, increasing the cAMP signaling aspects and restoring the antioxidant mechanisms. •OBX rats showed depression-like behavior.•OBX rats showed alter HPA axis, oxidant/antioxidant system and cAMP signaling.•Rolipram reversed the depression-like behavior in OBX rats.•Rolipram normalized alter HPA axis, oxidant/antioxidant system and cAMP signaling.•Rolipram effect may relate to HPA axis, cAMP/CREB/BDNF and antioxidant mechanism.</description><identifier>ISSN: 0091-3057</identifier><identifier>EISSN: 1873-5177</identifier><identifier>DOI: 10.1016/j.pbb.2015.02.017</identifier><identifier>PMID: 25712174</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Behavioral paradigms ; Depression ; Neurobiological markers ; Olfactory bulbectomy ; Oxidative stress ; Rolipram</subject><ispartof>Pharmacology, biochemistry and behavior, 2015-05, Vol.132, p.20-32</ispartof><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-f5ee916482ec3f7b7c63a22333145621c16b0d5c7efe6848ade33e06d9b9f7e13</citedby><cites>FETCH-LOGICAL-c452t-f5ee916482ec3f7b7c63a22333145621c16b0d5c7efe6848ade33e06d9b9f7e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0091305715000581$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25712174$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jindal, Ankur</creatorcontrib><creatorcontrib>Mahesh, Radhakrishnan</creatorcontrib><creatorcontrib>Bhatt, Shvetank</creatorcontrib><title>Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: Involvement of hypothalamic–pituitary–adrenal axis, cAMP signaling aspects and antioxidant defense system</title><title>Pharmacology, biochemistry and behavior</title><addtitle>Pharmacol Biochem Behav</addtitle><description>Olfactory bulbectomy (OBX) model has been proposed as a well documented model of depression. Accumulated evidences suggest that cAMP selective PDE4 enzyme plays an important role in the pathophysiology of depression disorder. Moreover, PDE4 inhibitors have shown antidepressant-like effect in behavioral despair models. However, the potential of PDE4 inhibitors to produce antidepressant-like effect in OBX model and their underlying mechanism(s) has not been adequately addressed. The present study was designed to investigate the possible antidepressant-like effects and underlying mechanism of rolipram in OBX model. The effects of rolipram were measured in a battery of behavioral paradigms, including hyperactivity in open field test (OFT), anhedonia behavior in sucrose consumption test, open arm activity in elevated plus maze test (EPM) and emotional scores in hyperemotionality test. The underlying signaling mechanisms were also investigated by measuring serum corticosterone (CORT), brain-derived neurotrophic factor (BDNF) and brain oxidant/antioxidant levels. Treatment with rolipram (0.5 and 1mg/kg, p.o., 14days) significantly improved the behavioral anomalies (decreased the hyperactivity, open arm activity and hyperemotionality scores, whereas, increased sucrose consumption). Further, rolipram significantly decreased the CORT level and increased cAMP, pCREB and BDNF levels. Additionally, rolipram reduced oxidative–nitrosative stress markers (lipid peroxidation and nitrite levels) and restored the antioxidant enzyme level, including reduced glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT), indicating attenuation of oxidative–nitrosative stress. Our results revealed that antidepressant-like effects of rolipram in OBX model may be mediated by modulating the hypothalamic–pituitary–adrenal (HPA) axis activity, increasing the cAMP signaling aspects and restoring the antioxidant mechanisms. •OBX rats showed depression-like behavior.•OBX rats showed alter HPA axis, oxidant/antioxidant system and cAMP signaling.•Rolipram reversed the depression-like behavior in OBX rats.•Rolipram normalized alter HPA axis, oxidant/antioxidant system and cAMP signaling.•Rolipram effect may relate to HPA axis, cAMP/CREB/BDNF and antioxidant mechanism.</description><subject>Behavioral paradigms</subject><subject>Depression</subject><subject>Neurobiological markers</subject><subject>Olfactory bulbectomy</subject><subject>Oxidative stress</subject><subject>Rolipram</subject><issn>0091-3057</issn><issn>1873-5177</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqFks1u1DAQxyMEokvhAbggHzl0F38kcRZOVQWlUhEcytly7El3Vokd7Oyq4cQ78Ia98hLMagtHOIzGsn_zH89HUbwUfCW4qN9sV2PbriQX1YrLFRf6UbEQjVbLSmj9uFhwvhZLxSt9UjzLecs5L2WtnxYnstJCCl0uil838wisZOMmZjKPkCdINgOD8H0egGHYYItTTGcsxR7HZAeWILsdZNbCxu4xJtszDx06nDLxLPaddRQxs3bXt0DHYWZD9NBnFjtCRxLIGMNbdhX2sd_DAGE6PG3mMU4b29sB3f2PnyNOO5xsmulsfYJAiewd5jPmzj99YRlv6QbDLbN5pDSZ2eDJJox36MkffgWBaskzVTU8L550ts_w4sGfFl8_vL-5-Li8_nx5dXF-vXRlJadlVwGsRV02EpzqdKtdrayUSilRVrUUTtQt95XTJF43ZWM9KAW89ut23WkQ6rR4fdQdU_xGfZrMgNlB39sAcZeNaGRdC6FU9X9UK9koSSyh4oi6FHNO0Jkx4UDNMYKbwzqYraF1MId1MFwaWgeKefUgv2sH8H8j_syfgHdHgGYDe4RkskMIDjwm6qjxEf8h_xvuqs73</recordid><startdate>20150501</startdate><enddate>20150501</enddate><creator>Jindal, Ankur</creator><creator>Mahesh, Radhakrishnan</creator><creator>Bhatt, Shvetank</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QR</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20150501</creationdate><title>Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: Involvement of hypothalamic–pituitary–adrenal axis, cAMP signaling aspects and antioxidant defense system</title><author>Jindal, Ankur ; Mahesh, Radhakrishnan ; Bhatt, Shvetank</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-f5ee916482ec3f7b7c63a22333145621c16b0d5c7efe6848ade33e06d9b9f7e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Behavioral paradigms</topic><topic>Depression</topic><topic>Neurobiological markers</topic><topic>Olfactory bulbectomy</topic><topic>Oxidative stress</topic><topic>Rolipram</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jindal, Ankur</creatorcontrib><creatorcontrib>Mahesh, Radhakrishnan</creatorcontrib><creatorcontrib>Bhatt, Shvetank</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacology, biochemistry and behavior</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jindal, Ankur</au><au>Mahesh, Radhakrishnan</au><au>Bhatt, Shvetank</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: Involvement of hypothalamic–pituitary–adrenal axis, cAMP signaling aspects and antioxidant defense system</atitle><jtitle>Pharmacology, biochemistry and behavior</jtitle><addtitle>Pharmacol Biochem Behav</addtitle><date>2015-05-01</date><risdate>2015</risdate><volume>132</volume><spage>20</spage><epage>32</epage><pages>20-32</pages><issn>0091-3057</issn><eissn>1873-5177</eissn><abstract>Olfactory bulbectomy (OBX) model has been proposed as a well documented model of depression. Accumulated evidences suggest that cAMP selective PDE4 enzyme plays an important role in the pathophysiology of depression disorder. Moreover, PDE4 inhibitors have shown antidepressant-like effect in behavioral despair models. However, the potential of PDE4 inhibitors to produce antidepressant-like effect in OBX model and their underlying mechanism(s) has not been adequately addressed. The present study was designed to investigate the possible antidepressant-like effects and underlying mechanism of rolipram in OBX model. The effects of rolipram were measured in a battery of behavioral paradigms, including hyperactivity in open field test (OFT), anhedonia behavior in sucrose consumption test, open arm activity in elevated plus maze test (EPM) and emotional scores in hyperemotionality test. The underlying signaling mechanisms were also investigated by measuring serum corticosterone (CORT), brain-derived neurotrophic factor (BDNF) and brain oxidant/antioxidant levels. Treatment with rolipram (0.5 and 1mg/kg, p.o., 14days) significantly improved the behavioral anomalies (decreased the hyperactivity, open arm activity and hyperemotionality scores, whereas, increased sucrose consumption). Further, rolipram significantly decreased the CORT level and increased cAMP, pCREB and BDNF levels. Additionally, rolipram reduced oxidative–nitrosative stress markers (lipid peroxidation and nitrite levels) and restored the antioxidant enzyme level, including reduced glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT), indicating attenuation of oxidative–nitrosative stress. Our results revealed that antidepressant-like effects of rolipram in OBX model may be mediated by modulating the hypothalamic–pituitary–adrenal (HPA) axis activity, increasing the cAMP signaling aspects and restoring the antioxidant mechanisms. •OBX rats showed depression-like behavior.•OBX rats showed alter HPA axis, oxidant/antioxidant system and cAMP signaling.•Rolipram reversed the depression-like behavior in OBX rats.•Rolipram normalized alter HPA axis, oxidant/antioxidant system and cAMP signaling.•Rolipram effect may relate to HPA axis, cAMP/CREB/BDNF and antioxidant mechanism.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25712174</pmid><doi>10.1016/j.pbb.2015.02.017</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0091-3057
ispartof Pharmacology, biochemistry and behavior, 2015-05, Vol.132, p.20-32
issn 0091-3057
1873-5177
language eng
recordid cdi_proquest_miscellaneous_1826611335
source Elsevier ScienceDirect Journals
subjects Behavioral paradigms
Depression
Neurobiological markers
Olfactory bulbectomy
Oxidative stress
Rolipram
title Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: Involvement of hypothalamic–pituitary–adrenal axis, cAMP signaling aspects and antioxidant defense system
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T09%3A59%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Type%204%20phosphodiesterase%20enzyme%20inhibitor,%20rolipram%20rescues%20behavioral%20deficits%20in%20olfactory%20bulbectomy%20models%20of%20depression:%20Involvement%20of%20hypothalamic%E2%80%93pituitary%E2%80%93adrenal%20axis,%20cAMP%20signaling%20aspects%20and%20antioxidant%20defense%20system&rft.jtitle=Pharmacology,%20biochemistry%20and%20behavior&rft.au=Jindal,%20Ankur&rft.date=2015-05-01&rft.volume=132&rft.spage=20&rft.epage=32&rft.pages=20-32&rft.issn=0091-3057&rft.eissn=1873-5177&rft_id=info:doi/10.1016/j.pbb.2015.02.017&rft_dat=%3Cproquest_cross%3E1732832133%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1732832133&rft_id=info:pmid/25712174&rft_els_id=S0091305715000581&rfr_iscdi=true